

Schedule-At-A-Glance

NOTE: The general session will take place in the Mendocino room. Breakfast and refreshment breaks will take place in the Burlingame room. The reception on January 25th at 5:00 PM will also take place in the Burlingame room. Lunch on January 26th will take place in the Atrium.

DAY 1 – Thursday, January 25

7:00 Registration and Breakfast

Session I: The Different Models for Partnering

Chair: Praveen Tipirneni, Senior Director, Corporate Development, Cubist Pharmaceuticals

7:55 Opening Remarks

Glenn Tillotson, Ph.D., Executive Director of Scientific Affairs, Replidyne, Inc.

8:00 Overview of the Different Models of Partnering

Yujiro Hata, M.B.A., Senior Vice President, Business Development, Enanta Pharmaceuticals

8:30 Merck-Paratek Partnership - A Case Study

Dennis Molnar, M.B.A., Vice President, Corporate Development, Paratek Pharmaceuticals

Ray Halls, Executive Director, Corporate Licensing, Merck & Co.

9:15 Idenix-Novartis: Landmark Deal for Building an Anti-infective Franchise

Susan Koppy, Senior Vice President, Corporate & Business Development, Idenix Pharmaceuticals

Mark Coflin, M.B.A., Global Executive Director, Alliance Management, Global Business Development & Licensing, Novartis

10:00 Refreshment Break

10:30 Theravance and Astellas Partnership – Designed for Success

David Brinkley, Senior Vice President, Commercial Development, Theravance, Inc.

11:00 Partnering for a Healthier World

Robert Jacks, M.B.A., Director, Licensing & Development, Pfizer

Schedule-At-A-Glance (*continued*)

Session II: Big Pharma Spin Offs into Stand-Alone Biotech Companies

Chair: Praveen Tipirneni, Senior Director, Corporate Development,
Cubist Pharmaceuticals

11:30 Big Pharma Spin offs into Stand-alone Biotech Companies: Where the Idea Came From

Rodger Novak, M.D., COO & Managing Director, Nabriva Therapeutics GmbH

12:00 Lunch on your own

Session III: Re-Emerging Pathogens

Chair: Glenn Tillotson, Ph.D., Executive Director of Scientific Affairs, Replidyne, Inc.

1:30 Overview of the Antibacterial Pipeline and Future Areas of Opportunity, 2007

Danielle Drayton, Ph.D., Senior Analyst, Decision Resources

2:00 Community-Acquired Methicillin-Resistant *Staphylococcus aureus* (CA-MRSA)

Sanjay K Jain, M.D., Assistant Professor of Pediatrics, Pediatric Infectious Diseases and Center for Tuberculosis Research, Johns Hopkins University School of Medicine

2:30 MRSA Community Acquired – Business Perspective

Scott Hopkins, M.D., Chief Clinical Officer, Rib-X Pharmaceuticals

3:00 Refreshment Break

3:30 BioPharm's Response to the Clostridium Difficile Epidemic: Discovering Value in an Old Agent while Generating New Opportunity

Aaron Pelta, M.B.A., Manager, Corporate Development, Cubist Pharmaceuticals

4:00 Gram-Negative Pathogens

Malcolm Page, Head, Discovery Biology, Baselia Pharmaceuticals

4:30 PcrV: The Achilles' Heal of *Pseudomonas aeruginosa*?

Mark Alfenito, Ph.D., Executive Vice President, Corporate Development, KaloBios Pharmaceuticals

5:00 Networking Reception

7:00 End of Day 1

Schedule-At-A-Glance

NOTE: The general session will take place in the Mendocino room. Breakfast and refreshment breaks will take place in the Burlingame room. The reception on January 25th at 5:00 PM will also take place in the Burlingame room. Lunch on January 26th will take place in the Atrium.

DAY 2 – Friday, January 26

8:00 Breakfast

Session IV: Novel Anti-Infectives

Chair: Glenn Tillotson, Ph.D., Executive Director of Scientific Affairs, Replidyne, Inc.

9:00 Inhaled Amphotericin

Eileen Neacy, Nektar

9:30 Nuvocid(TM): A Potent New Weapon in the Fight against Resistance

Rick Lundberg, Director of Business Development, Targanta Therapeutics

10:00 Innovative Approaches to Antiviral Drug Discovery and Development, and their Consequences for Partnering

Barbara Domayne-Hayman, D. Phil, Commercial Director, Arrow Therapeutics

10:30 Refreshment Break

11:00 Development of Rhinovirus Inhibitors

Jane Ryan, Ph.D., Vice President, Product Development, Biota Holdings Limited

11:30 The Next Generation Carbapenem: Broad Spectrum Empiric Coverage is Alive and Well

Klaus Esser, Ph.D., Chief Business Officer, Protez Pharmaceuticals

12:00 Lunch

Session V: Bioshield

1:30 PANEL: The Progress of Bioshield

Chair: Clem Lewin, Ph.D., Vice President of Biodefense and Policy, Acambis

Piers Whitehead, Vice President, Corporate and Business Development, Vaxgen

Beth Seidenberg, M.D., Executive in Residence, Kleiner Perkins

Caufield & Byers

Chris Colwell, Director, Healthcare Regulatory Affairs, BIO, Biotechnology

Industry Organization

Schedule-At-A-Glance (*continued*)

2:30 Refreshment Break

*Chair: Praveen Tipirneni, Senior Director, Corporate Development,
Cubist Pharmaceuticals*

3:00 Oral Presentations from Submitted Abstracts

Discovery, Optimization and Evaluation of CBR-2092: A Novel Agent for the Treatment of Serious Bacterial Infections

Michael Bakes, Cumbre Pharmaceuticals

Novel Therapy for *H. pylori* Eradication

Michael Naveh, Vecta Ltd.

Inhibition of Biofilm Formation by Zosteric Acid and Related Combinatorial Chemistries

Mike Mittelman, Cernofina, LLC

Session VI: New Outlooks in Infectious Diseases

*Chair: Praveen Tipirneni, Senior Director, Corporate Development,
Cubist Pharmaceuticals*

3:30 Clinical Perspectives and Epidemiology Must Direct Development of New Anti-infective Targets

Daniel M. Perlman, M.D., Founder and President of Greater Denver Infectious Disease Specialists

4:00 Bad Bugs, No Drugs – A View from Both Industry and the Marketplace

Ursula Theuretzbacher, Ph.D., The Center for Anti-Infective Agents

4:30 Conference Concludes